Form 13-F position report

OUTLOOK THERAPEUTICS INC

Reported by MORGAN STANLEY

OTLK CUSIP 69012T305 Manager CIK 0000895421

Reported 425,599 shares, up 386,125 (978.2%) from the prior quarter.

Reported value 1314.0%; share count 978.2% vs. the prior quarter.

Added
% of reported 13F value < 0.01% This manager · Q2 2025
Shares 425,599 Quarter-end amount reported
Reported value $680,958 Fair value at quarter end
Consecutive quarters held 19 Through Q2 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 54000
2022-03-31 93000
2022-06-30 51000
2022-09-30 74000
2022-12-31 102765
2023-03-31 175186
2023-06-30 350093
2023-09-30 32046
2023-12-31 198762
2024-03-31 142958
2024-03-31 0
2024-06-30 95098
2024-09-30 233512
2024-12-31 108470
2025-03-31 48158
2025-06-30 680958
2025-09-30 821
2025-12-31 9518
2026-03-31 783
2026-06-30 26960
2026-09-30 25847

Quarterly position history

How this manager's reported quarter-end position changed over time.

21 quarters
Quarterly reported position history for OUTLOOK THERAPEUTICS INC held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 45,069 +28,113 (165.8%) < 0.01% $25,847 2026-11-13
Q2 2026 Added 16,956 +13,150 (345.5%) < 0.01% $26,960 2026-08-13
Q1 2026 Reduced 3,806 -2,218 (-36.8%) < 0.01% $783 2026-05-15
Q4 2025 Added 6,024 +5,249 (677.3%) < 0.01% $9,518 2026-02-13
Q3 2025 Reduced 775 -424,824 (-99.8%) < 0.01% $821 2025-11-14
Q2 2025 Added 425,599 +386,125 (978.2%) < 0.01% $680,958 2025-08-15
Q1 2025 Reduced 39,474 -17,918 (-31.2%) < 0.01% $48,158 2025-05-15
Q4 2024 Added 57,392 +13,663 (31.2%) < 0.01% $108,470 2025-02-14
Q3 2024 Added 43,729 +30,843 (239.4%) < 0.01% $233,512 2024-11-14
Q2 2024 Added 12,886 +913 (7.6%) < 0.01% $95,098 2024-08-14
Q1 2024 Reduced 0 -504,471 (-100.0%) 0 $0 2024-05-15
Q1 2024 New 11,973 +11,973 (0.0%) < 0.01% $142,958 2024-05-15
Q4 2023 Added 504,471 +359,467 (247.9%) < 0.01% $198,762 2024-02-13
Q3 2023 Reduced 145,004 -56,199 (-27.9%) < 0.01% $32,046 2023-11-15
Q2 2023 Added 201,203 +40,482 (25.2%) < 0.01% $350,093 2023-08-14
Q1 2023 Added 160,721 +65,569 (68.9%) < 0.01% $175,186 2023-05-15
Q4 2022 Added 95,152 +33,687 (54.8%) < 0.01% $102,765 2023-02-14
Q3 2022 Added 61,465 +11,879 (24.0%) < 0.01% $74,000 2022-11-14
Q2 2022 Reduced 49,586 -2,202 (-4.3%) < 0.01% $51,000 2022-08-15
Q1 2022 Added 51,788 +12,325 (31.2%) < 0.01% $93,000 2022-05-13
Q4 2021 Reduced 39,463 -195,464 (-83.2%) < 0.01% $54,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

85 managers reported OUTLOOK THERAPEUTICS INC for Q2 2025.

Managers reporting OUTLOOK THERAPEUTICS INC in Q2 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Schonfeld Strategic Advisors LLC Reduced 1,364,809 -187,935 0.01% $2,183,692 6 qtrs
VANGUARD GROUP INC Added 1,251,598 +414,191 < 0.01% $2,002,557 6 qtrs
MORGAN STANLEY This report Added 425,599 +386,125 < 0.01% $680,958 6 qtrs
Steward Partners Investment Advisory LLC Unchanged 366,201 0 < 0.01% $585,921 6 qtrs
BlackRock Inc Reduced 339,896 -902,476 < 0.01% $543,834 4 qtrs
MILLENNIUM MANAGEMENT LLC New 338,571 +338,571 < 0.01% $541,714 1 qtr
GEODE CAPITAL MANAGEMENT LLC Reduced 265,631 -168,222 < 0.01% $425,114 6 qtrs
FMR LLC Reduced 170,502 -4,735 < 0.01% $272,803 6 qtrs
Squarepoint Ops LLC New 155,624 +155,624 < 0.01% $248,998 1 qtr
SUSQUEHANNA INTERNATIONAL GROUP LLP Added 117,769 +46,847 < 0.01% $188,430 5 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2025
Filed
August 15, 2025
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
424,537
Shared
0
None
1,062

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.